1.Changes in Causative Pathogens of Acute Cholangitis and Their Antimicrobial Susceptibility over a Period of 6 Years.
Jeong Seok KWON ; Jimin HAN ; Tae Won KIM ; Ji Hye OH ; Hyun Hee KWON ; Jin Tae JUNG ; Joong Goo KWON ; Eun Young KIM ; Ho Gak KIM
The Korean Journal of Gastroenterology 2014;63(5):299-307
BACKGROUND/AIMS: We evaluated changes of causative pathogen in acute cholangitis and their antimicrobial susceptibility over six years and differences between community-acquired and hospital-acquired acute cholangitis at our institution. METHODS: Medical records of 1,596 patients with acute cholangitis and biliary drainage between August 2006 and August 2012 were reviewed retrospectively. Cases were divided according to time: period 1 (August 2006-December 2008, n=645, 40.4%), period 2 (January 2009-August 2012, n=951, 59.6%). Cases were divided according to community-acquired cholangitis (n=1,397, 87.5%) and hospital-acquired cholangitis (n=199, 12.5%). Causative pathogens and antimicrobial susceptibility were investigated in each group. RESULTS: Causative pathogen was isolated from bile culture in 1,520 out of 1,596 cases (95.2%). The three most frequently isolated Gram-negative bacteria were extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (n=485, 30.4%), E. coli (n=237, 13.2%), and Citrobacter freundii (n=110, 6.9%). Between periods 1 and 2, prevalence of ESBL-producing E. coli and Klebsiella pneumoniae did not show significant change (36.7% vs. 32.1%, p=0.073; 6.6% vs. 6.2%, p=0.732). C. freundii showed a significant increase from period 1 to period 2 (1.7% vs. 13.2%, p=0.000). In both time periods, imipenem was the antimicrobial agent showing the highest rate of susceptibility (93.3% vs. 93.9%, p=0.783). Higher prevalence of ESBL-producing E. coli and C. freundii was observed in the hospital-acquired cholangitis group (52.1% vs. 31.2%, p=0.000; 15.9% vs. 7.3%, p=0.001). CONCLUSIONS: The most common causative pathogen of acute cholangitis was ESBL-producing E. coli. Prevalence of C. freundii increased over the time period. Imipenem should be reserved as an alternative for resistant pathogens.
Acute Disease
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/*pharmacology
;
Cholangitis/diagnosis/*microbiology
;
*Citrobacter freundii/drug effects/isolation & purification
;
Community-Acquired Infections/microbiology
;
Cross Infection/microbiology
;
Drug Resistance, Bacterial
;
*Escherichia coli/drug effects/isolation & purification
;
Female
;
Humans
;
Imipenem/pharmacology
;
*Klebsiella pneumoniae/drug effects/isolation & purification
;
Male
;
Microbial Sensitivity Tests
;
Middle Aged
;
Retrospective Studies
;
Time Factors
;
beta-Lactamases/metabolism
2.A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma.
Song I BAE ; Jong Eun YEON ; Jong Mee LEE ; Ji Hoon KIM ; Hyun Jung LEE ; Sun Jae LEE ; Sang Jun SUH ; Eileen L YOON ; Hae Rim KIM ; Kwan Soo BYUN ; Tae Seok SEO
Clinical and Molecular Hepatology 2012;18(3):321-325
Necrotizing pancreatitis is one of the rare complications of transcatheter arterial chemoembolization (TACE). Necrotizing pancreatitis after TACE may result from the development of ischemia caused by regurgitation of embolic materials into the vessels supplying the pancreas. We report a case of post-TACE necrotizing pancreatitis with abscess formation in a patient with hepatocellular carcinoma. The patient had suffered hepatic artery injury due to repetitive TACE; during his 25th TACE procedure he had submitted to selective catheterization of the feeding vessel from the dorsal pancreatic artery with a cytotoxic agent and Gelfoam particles. The patient complained of abdominal pain after the TACE procedure, and a CT scan led to a diagnosis of necrotizing pancreatitis with abscess formation. The pancreatic abscess progressed despite general management of the pancreatitis, including antibiotics. Percutaneous catheter drainage was performed, and the symptoms of the patient improved.
Abscess/microbiology
;
Aged
;
Anti-Bacterial Agents/therapeutic use
;
Carcinoma, Hepatocellular/*complications/*therapy
;
Chemoembolization, Therapeutic/*adverse effects
;
Cholangiopancreatography, Endoscopic Retrograde
;
Citrobacter freundii/isolation & purification
;
Drainage
;
Drug Resistance, Multiple, Bacterial
;
Enterobacteriaceae Infections/drug therapy
;
Hepatitis B/complications
;
Humans
;
Klebsiella/isolation & purification
;
Klebsiella Infections/drug therapy
;
Liver Cirrhosis/etiology
;
Liver Neoplasms/*complications/*therapy
;
Male
;
Necrosis/*diagnosis/etiology
;
Pancreatitis/*diagnosis/etiology
;
Tomography, X-Ray Computed
3.Identification of ACT-1 Plasmid-Mediated AmpC beta-Lactamase Producing Citrobacter freundii from a Chinese Patient.
Annals of Laboratory Medicine 2013;33(1):86-88
No abstract available.
Aged
;
Anti-Bacterial Agents/pharmacology/therapeutic use
;
Asian Continental Ancestry Group
;
Bacterial Proteins/genetics/*metabolism
;
China
;
Cilastatin/therapeutic use
;
Citrobacter freundii/drug effects/*enzymology/isolation & purification
;
Drug Combinations
;
Drug Resistance, Multiple, Bacterial
;
Humans
;
Imipenem/therapeutic use
;
Male
;
Microbial Sensitivity Tests
;
Plasmids/*metabolism
;
Respiratory Tract Infections/*diagnosis/drug therapy/microbiology
;
beta-Lactamases/genetics/*metabolism
4.First Detection of VIM-4 Metallo-beta-Lactamase-Producing Citrobacter freundii in China.
Annals of Laboratory Medicine 2013;33(1):84-85
No abstract available.
Aged
;
Anti-Bacterial Agents/pharmacology/therapeutic use
;
Cefotaxime/therapeutic use
;
China
;
Ciprofloxacin/therapeutic use
;
Citrobacter freundii/drug effects/*enzymology/isolation & purification
;
Drug Resistance, Multiple, Bacterial
;
Humans
;
Imipenem/pharmacology
;
Male
;
Microbial Sensitivity Tests
;
Respiratory Tract Infections/*diagnosis/drug therapy/microbiology
;
Thienamycins/pharmacology
;
beta-Lactamases/*metabolism